AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-118900774/agreement-signed-develop-iv.html" title="Facts and information about Agreement signed to develop IV terlipressin for Type 1 hepato-renal syndrome.">Agreement signed to develop IV terlipressin for Type 1 hepato-renal syndrome.</a>

Close Set up an RSS feed that alerts you when new articles from Pharma Business Week are available.

Frequently asked questions about RSS feeds

Agreement signed to develop IV terlipressin for Type 1 hepato-renal syndrome.

Pharma Business Week

| July 05, 2004 | COPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 JUL 5 - (NewsRx.com & NewsRx.net) -- ESP Pharma, Inc., a niche pharmaceutical company focused on the acquisition, marketing, and late-stage development of life-saving acute-care therapeutics, announced that it has entered into an agreement to acquire from Orphan Therapeutics, LLC, of Lebanon, New Jersey, rights to intravenous terlipressin, a novel therapeutic in phase III clinical trials for treating Type 1 hepato-renal syndrome (HRS).

Type 1 HRS is characterized by acute kidney failure associated with severe liver disease, a condition typically fatal within a few weeks of onset. The condition may be resolved with the kidneys resuming normal activity once liver …

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


ESP Pharma and Orphan Therapeutics in agreement to develop and commercialise IV...: News wire article from: Asia Africa Intelligence Wire June 8, 2004 700+ words
...Release) ESP Pharma Inc has entered...acquire from Orphan Therapeutics LLC of Lebanon...collaboration with ESP Pharma, Orphan Therapeutics has agreed...the drug. ESP Pharma Inc is committed...in 2003, Orphan Therapeutics is establishing...


ESP Pharma and Orphan Therapeutics in Agreement to Develop and Commercialize...: Press release article from: Business Wire June 8, 2004 700+ words
...Medical Need ESP Pharma, Inc., a niche...acquire from Orphan Therapeutics, LLC (Lebanon...the agreement, ESP Pharma agreed to upfront...collaboration with ESP, Orphan Therapeutics has agreed to...information about ESP Pharma is available...ESPPharma.com ...


ESP Pharma, Orphan Therapeutics enter agreement to develop novel treatment for...: Newspaper article from: Transplant News June 14, 2004 700+ words
ESP Pharma, Inc., Edison, NJ, announced it has entered into an agreement with Orphan Therapeutics, LLC, Lebanon, NJ to acquire the rights to Orphan's intravenous terlipressin, a novel therapeutic in Phase III clinical trials...


ESP Pharma Announces FDA Grants Orphan Drug Status to I.V. Terlipressin, a...: Press release article from: Business Wire November 10, 2004 700+ words
...EDISON, N.J. -- ESP Pharma, Inc. today announced...June 8, 2004, ESP Pharma acquired from Orphan Therapeutics, LLC (Lebanon...information about ESP Pharma is available on...ESPPharma.com About Orphan Therapeutics, LLC Orphan Therapeutics...


ESP Pharma announces FDA grants orphan drug status to IV Terlipressin, a Phase...: News wire article from: Asia Africa Intelligence Wire November 10, 2004 700+ words
...8 Jun 2004, ESP Pharma acquired from Orphan Therapeutics LLC exclusive...two companies, Orphan Therapeutics pursued the now...Designation. Orphan Therapeutics also agreed to...patient enrolment. ESP Pharma Inc is committed...


FDA grants ESP Pharma Orphan Drug status for IV Terlipressin for treating type...: Newspaper article from: Transplant News November 16, 2004 700+ words
ESP Pharma, Inc., xx, announced the...indication. On June 8, 2004, ESP Pharma acquired from Orphan Therapeutics, LLS, Lebanon, NJ, exclusive...Under terms of the agreement, Orphan Therapeutics pursued the now granted Orphan...


Protein Design Labs and Orphan Therapeutics report fast track designation for...: News wire article from: Asia Africa Intelligence Wire April 20, 2005 700+ words
...and privately held Orphan Therapeutics LLC reported that...owned subsidiary, ESP Pharma Inc, has acquired from Orphan Therapeutics exclusive marketing...the US and Canada. Orphan Therapeutics holds the US investigational...


PDL BioPharma Reports Results From Phase 3 Trial of Terlipressin In Type 1...: Press release article from: PR Newswire August 3, 2006 700+ words
...PDL. "We will work with Orphan Therapeutics to further analyze the study...following its acquisition of ESP Pharma in March 2005. The original agreement between ESP Pharma and Orphan Therapeutics was established in June 2004...


U.S. FDA grants orphan drug status to I.V. Terlipressin.: Newspaper article from: Life Science Weekly December 21, 2004 700+ words
...com & NewsRx.net) -- ESP Pharma, Inc., announced that...announced, on June 8, 2004, ESP Pharma acquired from Orphan Therapeutics, LLC, (OT; Lebanon...between the two companies, Orphan Therapeutics pursued the now-granted...


Agreement signed to develop IV terlipressin for Type 1 hepato-renal syndrome.: Newspaper article from: Obesity, Fitness & Wellness Week July 10, 2004 700+ words
...NewsRx.net) -- ESP Pharma, Inc., a niche...acquire from Orphan Therapeutics, LLC, of Lebanon...the agreement, ESP Pharma agreed to upfront...collaboration with ESP, Orphan Therapeutics has agreed to...president of Orphan Therapeutics commented ...

For more facts and information, see all results

Source: HighBeam Research, Agreement signed to develop IV terlipressin for Type 1 hepato-renal...

The AccessMyLibrary advertising network includes: